title: Low-molecular weight heparin enoxaparin in the treatment of acute coronary syndromes without ST segment elevation.
abstract: OBJECTIVE
  We compared the incidence of adverse cardiac outcomes of enoxaparin vs unfractionated heparin in the management of ACS-NSTE.
  
  
  BACKGROUND
  Low-molecular-weight heparins are the potential new standard in the treatment of acute coronary syndromes without ST-segment elevation (ACS-NSTE). The benefit is addressed to significant diminution of the adverse clinical events--recurrent angina (RA), myocardial infarction (MI), heart failure (HF), cerebrovascular insult (ICV), coronary artery by-pass graft (CABG), percutaneous coronary intervention (PCI) and death.
  
  
  METHODS
  Sixty patients with ACS-NSTE were randomised to receive Enoxaparin 1 mg/kg body weight s.c twice daily (n=30) and unfractionated heparin (Heparin - "Biochemie" 25.000 IU/5 ml), according to Rashke nomogram (n=30). The end point were RA, MI, HF, ICV, CABG, PCI and death at day 180. The Kaplan-Meier estimation technique was used to compared the time to events for two treatments. A p<0.05 was considered to indicate significance.
  
  
  RESULTS
  For 180 days, RA, MI, HF, ICV and death were lower in the Enoxaparin vs UFH group (36.6% vs 73.3%, p=0.001), (30% vs 53.3%, p=0.05), (13.3% vs 23.3%, p=0.31), (3.3% vs 10%, p=0.29), (3.3% vs 10%, p=0.31), respectively. CABG were similar 13.3% (p=0.96). PCI were performing in 33.3% in UFH vs 90% in LMWH (p=0.0001).
  
  
  CONCLUSIONS
  The use of Enoxaparin in ACS-NSTE schows impressive decrease of incidence of ischemic events (Fig. 7, Ref. 8). Full Text (Free, PDF) www.bmj.sk.
authors.affiliation: Department of Cardiology, Military Hospital, Skopje, Macedonia. mitrovska2000@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Mitrovska
authors.forename: S
authors.initials: S
authors.lastname: Jovanova
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D006493:Heparin